Capture_brand and logo.PNG
Morphic to Present at November Investor Conferences
10 nov. 2023 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
29 août 2023 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic to Present at the Jefferies Global Healthcare Conference
06 juin 2023 16h05 HE | Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05 mai 2023 10h30 HE | Morphic Therapeutic
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...
Capture_brand and logo.PNG
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
03 mai 2023 00h13 HE | Morphic Therapeutic
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious...
Capture_brand and logo.PNG
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
24 avr. 2023 16h01 HE | Morphic Therapeutic
WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic-Brand-NoTMLogo-RGB-082321-01.png
Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h00 HE | Morphic Therapeutic
WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces Participation in Upcoming Investor Conferences
03 sept. 2020 16h30 HE | Morphic Therapeutic
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
MorphicLogo.jpg
Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
25 août 2020 06h30 HE | Morphic Therapeutic
AbbVie to pay Morphic license fee of $20 million, with future potential milestones and royalties AbbVie to lead further development and commercialization WALTHAM, Mass., Aug. 25, 2020 (GLOBE...
MorphicLogo.jpg
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
10 août 2020 07h00 HE | Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...